Hospitalist treatment of CAP and cellulitis using objective criteria to select patients

Infections in Medicine

Volumn 20, Issue 8, 2003, Pages 379-390+399

  Dall, Lawrence ^a,b   Peddicord, Tom ^c   Peterson, Sanford ^d   Simmons, Tom ^a   Dall, Tyler ^e  

^a Midwest Hospital Specialists   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Hosp Internal Medicine Specialists   (United States)

^e UNIVERSITY OF KANSAS   (United States)

Author keywords

Antibiotics; Cellulitis; Hospitalist; Pneumonia, community acquired

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEFTRIAXONE; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; OXYGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CELLULITIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOME CARE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MORTALITY; PATIENT CODING; PATIENT SATISFACTION; PATIENT SELECTION; PNEUMONIA; STANDARDIZATION; STATISTICAL ANALYSIS;

EID: 0041351873     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33:203-209.
2. Wai AO, Frighetto L, Marra CA, et al. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics. 2000;18:451-457.
3. Johansson E, Bjorkholm M, Wredling R. et al. Outpatient parenteral antibiotic therapy in patients with haematological, malignancies. A pilot study of an early discharge strategy. Support Care Cancer. 2001;8:619-624.
4. Esposito S. Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy. Chemotherapy. 2001; 47(suppl 1):33-40.
5. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotheraphy. 2001;47(suppl 1):17-23
6. Poretz DM. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug delivery device: a multicenter trial. HIAT Study Group. Am J Med. 1994;97:23-27.
7. Li JZ, Willke RJ, Rittenhouse BE, Glick HA. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy. 2002;22(2 pt 2):45S-54S.
8. Martone WJ, Jarvis WR, Culver DH, Haley RW. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, eds. Hospital Infections. Boston: Little, Brown and Company; 1992:577-596.
9. Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy. 2002;22(2 pt 2): 63S-70S.
10. McCormick D, Fine M, Coley C, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med. 1999;107:5-12.'
11. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820-837.
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
13. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med. 2001;161:61-65.
14. Ewig S, Schafer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J. 2000;16:1193-1201
15. Moran GJ. New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. Pharmacotherapy. 2001; 21(7 pt 2):95S-99S.
16. Chan C, Shibl A, Memish Z, Zhanel G. Community acquired pneumonia (CAP): an update. J Chemother. 2001;13(suppl 1):23-27.
17. Niederman MS, Mandell LA, Anzueto A, et al, for the American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
18. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med. 2000;109:378-385.
19. Englert J, Davis KM, Koch KE. Using clinical practice analysis to improve care. Jt Comm J Qual Improv. 2001;27:291-301.
20. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283:749-755.